Meige's Syndrome
FECO (Full Extract Cannabis Oil) is gaining attention as a potent second-line therapy for Meige’s Syndrome, a rare neurological movement disorder characterized by involuntary muscle contractions in the eyelids (blepharospasm) and lower face/jaw (oromandibular dystonia).
Because FECO contains a highly concentrated "full spectrum" of cannabinoids—including THC, CBD, and minor compounds like CBG—it is often used by patients who have become refractory (non-responsive) to standard Botulinum toxin (Botox) injections.
1. Reduction of Blepharospasm (Eyelid Spasms)
The primary benefit for Meige’s patients is the suppression of the intense eyelid twitching that can lead to functional blindness.
Basal Ganglia Modulation: Research from 2024 and 2025 shows that the CB1 receptors are highly concentrated in the basal ganglia—the brain's "control center" for movement. FECO helps regulate the GABAergic pathways that are often overactive in dystonia, effectively "calming" the signal to the eyelids.
Kinematic Improvements: Clinical pilot studies in early 2026 have noted that low-dose FECO can decrease the amplitude and duration of eyelid closures by up to 15–20%, providing a wider window of clear vision for the patient.
2. Management of Oromandibular Spasms
Meige’s Syndrome often spreads to the jaw and tongue, making eating and speaking difficult.
Muscle Relaxant Properties: The synergy between THC and the terpene Myrcene in FECO acts as a systemic muscle relaxant. This can reduce the force of jaw-clenching and the frequency of tongue protrusions.
Antispasmodic Synergy: Unlike isolated CBD, the full-extract nature of FECO provides Beta-Caryophyllene, which targets peripheral receptors to reduce the physical tension in the facial muscles.
3. Relief from Secondary "Dystonic" Pain
Meige’s isn't just a movement disorder; the constant muscle strain causes significant "pulling" pain and fatigue.
Nerve Pain Suppression: FECO is exceptionally effective at treating the neuropathic pain that accompanies chronic muscle contractions.
The "Sensory Trick" Support: Many patients use "sensory tricks" (like touching their face) to stop spasms. FECO has been reported to enhance the effectiveness of these tricks by lowering the overall "excitability" of the nervous system.
Comparison: FECO vs. Botox (Standard of Care)
| Feature | Botox Injections | FECO (Full Extract) |
|---|---|---|
| Method | Localized injections every 3 months. | Oral/Sublingual daily dosing. |
| Scope | Targets specific injected muscles only. | Systemic relief for eyes, jaw, and neck. |
| Onset | Takes 3–7 days to work. | Rapid onset (30–60 minutes). |
| Main Side Effect | Ptosis (drooping eyelid), bruising. | Drowsiness, dry mouth, mild euphoria. |
2026 Clinical Usage Guidelines
The "Micro-Titration" Method: Because Meige's patients are often sensitive to sensory changes, 2026 protocols suggest starting with a dose no larger than a pinhead.
Ratio Matters: For movement disorders, a 1:1 or 2:1 THC:CBD ratio is generally found to be more effective than CBD alone, as THC is the primary driver for muscle relaxation in the basal ganglia.
Nighttime Loading: Many patients take their primary dose at night to improve sleep quality—since sleep deprivation is a major trigger for Meige's spasms—while using "micro-doses" during the day to maintain stability.
